Drug Profile


Alternative Names: MK-7965; PS-095760; SCH 727965; SCHOOL 727965

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pharmacopeia
  • Developer Merck & Co
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; CDC2 protein kinase inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia
  • Phase I/II Solid tumours
  • Phase I Haematological malignancies
  • No development reported Breast cancer; Non-small cell lung cancer
  • Discontinued Leukaemia; Mantle-cell lymphoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2016 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater) in USA (IV) (NCT02684617)
  • 19 Feb 2016 Merck Sharp & Dohme plans the phase Ib KEYNOTE-155 trial for Chronic lymphocytic leukaemia, Multiple myeloma and Diffuse large B-cell lymphoma (Second-line therapy or greater, Combination therapy) in USA (IV) (NCT02684617)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top